Question 1

Does RhumbLine Advisers own CYTK stock?

Accepted Answer

Yes. As of its Q2 2026 13F, RhumbLine Advisers holds 421,799 shares of CYTK (Cytokinetics), worth $35.9M.

Question 2

How many shares of CYTK does RhumbLine Advisers own?

Accepted Answer

As of its Q2 2026 13F, RhumbLine Advisers holds 421,799 shares of CYTK (Cytokinetics).

Question 3

What is RhumbLine Advisers' CYTK position worth?

Accepted Answer

As of its Q2 2026 13F, RhumbLine Advisers' CYTK position is worth $35.9M.

Question 4

Is RhumbLine Advisers buying or selling CYTK?

Accepted Answer

In Q2 2026, RhumbLine Advisers increased its CYTK position by 52,224 shares (+14.1%).

Question 5

When did RhumbLine Advisers first buy CYTK?

Accepted Answer

RhumbLine Advisers already held CYTK in its Q4 2018 13F, the earliest on record, and has listed it in 31 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Increased	421,799	+14.1%	$35.9M	0.0%	$85.19	33
2026-Q1	Increased	369,575	+3.5%	$24.4M	0.0%	$65.91	30
2025-Q4	Decreased	356,995	-7.5%	$22.7M	0.0%	$63.54	0
2025-Q3	Decreased	385,813	-1.1%	$21.2M	0.0%	$54.96	0
2025-Q2	Increased	389,940	+4.3%	$12.9M	0.0%	$33.04	29
2025-Q1	Decreased	373,855	-2.6%	$15M	0.0%	$40.19	0
2024-Q4	Increased	383,883	+1.4%	$18.1M	0.0%	$47.04	29
2024-Q3	Decreased	378,676	-0.1%	$20M	0.0%	$52.80	0